Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC
Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99a and REVTx-99b. In addition to Revelation's therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will present a corporate overview at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
聖迭戈，2022年3月22日(環球網)--專注於開發基於免疫學的預防和治療疾病療法的臨牀期生命科學公司--啟迪生物科學公司(納斯達克：REVB)(以下簡稱“公司”或“啟迪”)今天宣佈，其首席執行官詹姆斯·羅克將在2022年虛擬增長大會上介紹公司概況，該大會由Maxim Group LLC提交，M-Vest主辦，時間為3月28日至30日上午9：00。-下午5：00美國東部夏令時。
Sign up here to access the presentation
在此處註冊以訪問演示文稿
About Revelation Biosciences Inc.
關於啟迪生物科學公司。
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99a and REVTx-99b. In addition to Revelation's therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.
啟迪生物科學公司是一家臨牀階段的生命科學公司，專注於開發基於免疫學的預防和治療疾病的療法。啟示錄有幾款候選產品正在開發中。REVTx-99a是主要的候選治療藥物，是一種鼻腔免疫調節劑，用於預防或治療由各種呼吸道病毒引起的感染，如SARS-CoV-2，包括其變種、A和B流感、副流感、鼻病毒和RSV。REVTx-99b正在開發用於其他適應症，如過敏性鼻炎和慢性鼻塞。REVTx-200是一種鼻腔免疫調節劑輔助劑，可與肌肉接種結合使用，以獲得更完全的免疫。REVTx-200基於與REVTx-99a和REVTx-99b相同的技術。除了啟示錄的治療流水線外，啟示錄還在開發REVDx-501，這是一種快速的家庭使用診斷方法，可以用於檢測任何呼吸道病毒感染，無論病毒類型或毒株，而不需要專門的儀器。
For more information on Revelation, please visit .
有關《啟示錄》的更多信息，請訪問。
Company Contacts
公司聯繫人
Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
桑德拉·韋德里克
投資者關係和人力資源部副總裁
啟示錄生物科學公司。
電子郵件：svedrick@revbiosciences.com
and
和
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
切斯特·齊格蒙特，III
首席財務官
啟示錄生物科學公司。
電子郵件：czygmont@revbiosciences.com